Clinical Trials Directory

Trials / Conditions / Recurrent Childhood Soft Tissue Sarcoma

Recurrent Childhood Soft Tissue Sarcoma

21 registered clinical trials studyying Recurrent Childhood Soft Tissue Sarcoma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingEx Vivo Drug Sensitivity Testing and Multi-Omics Profiling
NCT05857969
Florida International UniversityPhase 1
CompletedEx Vivo Drug Sensitivity Testing and Mutation Profiling
NCT03860376
Florida International University—
Active Not RecruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03210714
National Cancer Institute (NCI)Phase 2
CompletedOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist
NCT03233204
National Cancer Institute (NCI)Phase 2
CompletedStudying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
NCT01567046
Children's Oncology Group—
UnknownTrabectedin and Irinotecan for Refractory Pediatric Sarcomas
NCT02509234
Technical University of Munich—
CompletedCixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
NCT01614795
National Cancer Institute (NCI)Phase 2
Active Not RecruitingBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With
NCT01552434
M.D. Anderson Cancer CenterPhase 1
CompletedAlisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
NCT01154816
Children's Oncology GroupPhase 2
CompletedPazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Tr
NCT00929903
National Cancer Institute (NCI)Phase 1
CompletedCixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00831844
National Cancer Institute (NCI)Phase 2
CompletedCixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metasta
NCT00720174
National Cancer Institute (NCI)Phase 1
CompletedTrabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of T
NCT00070109
Children's Oncology GroupPhase 2
CompletedIxabepilone in Treating Young Patients With Refractory Solid Tumors
NCT00331643
National Cancer Institute (NCI)Phase 2
CompletedOxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270
National Cancer Institute (NCI)Phase 1
CompletedOxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme
NCT00091182
National Cancer Institute (NCI)Phase 2
CompletedTanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
NCT00093821
National Cancer Institute (NCI)Phase 1
CompletedErlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
NCT00077454
National Cancer Institute (NCI)Phase 1
CompletedImatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
NCT00030667
National Cancer Institute (NCI)Phase 2
CompletedFlavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
NCT00012181
National Cancer Institute (NCI)Phase 1
CompletedCollecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Sof
NCT00919269
Children's Oncology Group—